ARV-393, a PROTAC BCL6 degrader, combined with the CD20×CD3 bispecific glofitamab in a preclinical model of high-grade B-cell lymphoma (HGBCL)
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1520
Abstract: Background: Despite significant progress made in the treatment of non-Hodgkin lymphoma (NHL) through advancements with immunochemotherapy, autologous stem cell transplantation, chimeric antigen receptor T-cell therapies, bispecific antibodies, and other targeted therapies, many patients ultimately experience… read more here.
Keywords: arv 393; combination; cell; bcl6 ... See more keywords